Thomas Locke

Researchers characterise the liver stage of Plasmodium vivax, and scientists discover that two chemicals can inhibit growth of Plasmodium infection.

Researchers find that the malaria parasite mimics a natural molecule that inhibits the release of NK cells, and the effect of insecticide resistance on the reproductive potential of Anopheles coluzzii mosquitoes has been revealed.

Zambian study reveals that mass drug administration is safe, logistically feasible, accepted by communities, and effective in reducing malaria prevalence in the short term, and the Medicines for Malaria Venture launch Malaria Libre, an open-source drug discovery programme. 

The prevalence of insecticide resistance increases in Africa and researchers find that the malaria parasite interferes with red blood cell development to ensure gametocyte maturation.

CDK5 regulates atypical cell division in gametogony and is essential for DNA replication, and researchers assess whether two experimental vaccines can be combined to create a multistage vaccine against malaria.

Researchers evaluate the immunogenicity of the AGS-v vaccine which targets saliva produced by Anopheles gambiae mosquitoes.

New mutations to the quinoline drug family identified in South America and Asia are not prevalent in Africa and scientists evaluate a new field-based malaria blood test.

Artefenomel is assessed against Plasmodium vivax infection in humans to determine the minimum effective dose required for parasite clearance and LSHTM launch a beta version of The Global Vector Hub.

The spleen plays a major role in the expression of P. vivax genes and the production of antigens associated with clinical protection, and scientists develop an AI that can detect Plasmodium infection in the blood.